This case study focuses on a collaboration between GENEWIZ and a large pharmaceutical client to develop a more effective approach for screening engineered cell lines via an automated, interactive NGS-based platform. This powerful technology permits the identification of all classes of genetic disruptions, including mono-allelic, homozygous, and heterozygous biallelic modifications.